<DOC>
	<DOCNO>NCT01484145</DOCNO>
	<brief_summary>The purpose study determine much terbinafine deliver nail bed treatment number modification previously study method iontophoretic delivery terbinafine gel . Iontophoretic delivery involve use small electric charge deliver drug across skin nail .</brief_summary>
	<brief_title>Deposition Terbinafine After Iontophoretic Application ETS Terbinafine Gel Subjects With Distal Subungual Onychomycosis Great Toenail</brief_title>
	<detailed_description />
	<mesh_term>Onychomycosis</mesh_term>
	<mesh_term>Terbinafine</mesh_term>
	<criteria>Positive KOH 2575 % involvement visible nail . Nail plate must &lt; 3 mm thick . Must sign informed consent . Must agree avoid type pedicure application nail polish product nail cosmetic toenail screen visit Day 28 . Female subject childbearing potential must agree take measure avoid pregnancy day Day 28 Must agree avoid use oral antifungal topical terbinafine anywhere body day Day 28 . Topical antifungal terbinafine use body foot Day 0 . Presence proximal subungual onychomycosis white superficial onychomycosis Fungal involvement majority lunula Subjects psoriasis , eczema , abnormality could result clinically abnormal nail Presence dermatophytoma onychomycotic spike exclusively lateral groove involvement Traumatized dystrophic target great toenail . Known diabetic Subjects peripheral vascular disease Subjects immunosuppressed ( chronic corticosteroid therapy , solid organ bone marrow transplantation , cytotoxic chemotherapy within previous 12 month ( plan within next 12 month ) , HIV infection . Use systemic corticosteroid within 30 day precede Day 0 Use topical antifungal foot precede 30 day Day 0 Day 28 Use topical terbinafine 30 day prior treatment Day 28 Use systemic antifungal precede 120 day Day 0 Day 28 Use investigational drug ( ) within 30 day ( 120 day systemic antifungal ) precede Day 0 Day 28 Has previously participate study Is pregnant nursing mother Women child bear potential use adequate form contraception ( abstinence ) Subjects pacemakers/automatic implantable cardioverter/defibrillators Subjects implantable electronic device . Subjects bleed disorder use warfarin blood coagulation modulator include aspirin 14 day prior treatment Day 28</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Onychomycosis</keyword>
	<keyword>Nail fungus</keyword>
	<keyword>Tinea Unguium</keyword>
</DOC>